论文部分内容阅读
目的观察厄贝沙坦联合胺碘酮预防阵发性心房颤动复发率及对左房内径的影响。方法阵发性心房颤动患者60例,随机分为治疗组(厄贝沙坦加胺碘酮合用),对照组(胺碘酮单用),随访12个月,观察两组心房颤动复发率、左心房内径变化。结果12个月内治疗组有3例退出,完成27例;对照组退出2例,完成28例。随访12个月,治疗组复发率为22.22%(6/27),对照组复发率为46.43%(13/28),两组比较差异有统计学意义(P<0.05);两组左心房内径治疗前后比较差异无统计学意义(P>0.05)。结论厄贝沙坦联合胺碘酮能有效预防阵发性心房颤动复发,维持窦性心律。
Objective To observe the effect of irbesartan and amiodarone on the recurrence rate of paroxysmal atrial fibrillation and its effect on the left atrial diameter. Methods 60 patients with paroxysmal atrial fibrillation were randomly divided into treatment group (irbesartan plus amiodarone combined), control group (amiodarone alone), followed up for 12 months, observed the recurrence rate of atrial fibrillation, Left atrial diameter changes. Results In 12 months, 3 patients in the treatment group withdrew and 27 patients completed. In the control group, 2 patients quit and 28 patients completed. The follow-up of 12 months showed that the recurrence rate was 22.22% (6/27) in the treatment group and 46.43% (13/28) in the control group, with significant difference between the two groups (P <0.05) There was no significant difference between before and after treatment (P> 0.05). Conclusion Irbesartan combined with amiodarone can effectively prevent the recurrence of paroxysmal atrial fibrillation and maintain sinus rhythm.